Results 331 to 340 of about 22,658,854 (391)
Some of the next articles are maybe not open access.
New England Journal of Medicine, 1985
We describe here the preliminary results of the systemic administration of autologous lymphokine-activated killer (LAK) cells and the recombinant-derived lymphokine interleukin-2 to patients with advanced cancer.
S. Rosenberg +12 more
semanticscholar +1 more source
We describe here the preliminary results of the systemic administration of autologous lymphokine-activated killer (LAK) cells and the recombinant-derived lymphokine interleukin-2 to patients with advanced cancer.
S. Rosenberg +12 more
semanticscholar +1 more source
Annual Review of Immunology, 1984
In the past year there have been significant advances in understanding the role of interleukin-2. Its role in the activation of T cells by antigen-presenting cells, the structure-activity relationships between interleukin-2 and its receptor and the subsequent signaling have all become clearer.
openaire +4 more sources
In the past year there have been significant advances in understanding the role of interleukin-2. Its role in the activation of T cells by antigen-presenting cells, the structure-activity relationships between interleukin-2 and its receptor and the subsequent signaling have all become clearer.
openaire +4 more sources
Leukemia Research, 1990
Interleukin 2 receptors (IL-2-R) are composed of (at least) two chains: the alpha chain (or p55 or Tac) and the beta chain (or p70 or p75). The association of both chains constitutes high affinity IL2-R complexes (Kd congruent to 10-100 pM), whereas the alpha-chain or the beta chain alone bind IL-2 with low (Kd congruent to 5-50 nM) and intermediate ...
Maria Perrakis +7 more
openaire +2 more sources
Interleukin 2 receptors (IL-2-R) are composed of (at least) two chains: the alpha chain (or p55 or Tac) and the beta chain (or p70 or p75). The association of both chains constitutes high affinity IL2-R complexes (Kd congruent to 10-100 pM), whereas the alpha-chain or the beta chain alone bind IL-2 with low (Kd congruent to 5-50 nM) and intermediate ...
Maria Perrakis +7 more
openaire +2 more sources
Interleukin-2: inception, impact, and implications.
Science, 1988Interleukin-2 (IL-2), the first of a series of lymphocytotrophic hormones to be recognized and completely characterized, is pivotal for the generation and regulation of the immune response.
Kendall A. Smith
semanticscholar +1 more source
New England Journal of Medicine, 1988
Lymphocytes extracted from freshly resected melanomas can be expanded in vitro and can often mediate specific lysis of autologous tumor cells but not allogeneic tumor or autologous normal cells. We treated 20 patients with metastatic melanoma by means of
S. Rosenberg +15 more
semanticscholar +1 more source
Lymphocytes extracted from freshly resected melanomas can be expanded in vitro and can often mediate specific lysis of autologous tumor cells but not allogeneic tumor or autologous normal cells. We treated 20 patients with metastatic melanoma by means of
S. Rosenberg +15 more
semanticscholar +1 more source
Role of interleukin-2 release by lung T-cells in active pulmonary sarcoidosis.
American Review of Respiratory Disease, 2015Using a human T-cell line sensitive to interleukin-2 (IL-2), we evaluated supernatants of unstimulated, purified lung T-lymphocytes from patients with sarcoidosis and high-intensity alveolitis (active disease), patients with sarcoidosis and low-intensity
G. Hunninghake +4 more
semanticscholar +1 more source
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1994
Recombinant interleukin (IL)‐2 is a newly approved immunoregulatory protein produced by lymphocytes that exhibits a wide range of immunologic effects. It is a true biologic response modifier in that is has no known direct antitumor activity, but mediates its cytotoxicity through activation of effector cells including T cells, natural killer cells, and ...
J. Bruton, Jim M. Koeller
openaire +3 more sources
Recombinant interleukin (IL)‐2 is a newly approved immunoregulatory protein produced by lymphocytes that exhibits a wide range of immunologic effects. It is a true biologic response modifier in that is has no known direct antitumor activity, but mediates its cytotoxicity through activation of effector cells including T cells, natural killer cells, and ...
J. Bruton, Jim M. Koeller
openaire +3 more sources
Journal of Clinical Oncology, 1999
PURPOSE To determine the short- and long-term efficacy and toxicity of the high-dose intravenous bolus interleukin 2 (IL-2) regimen in patients with metastatic melanoma.
M. Atkins +12 more
semanticscholar +1 more source
PURPOSE To determine the short- and long-term efficacy and toxicity of the high-dose intravenous bolus interleukin 2 (IL-2) regimen in patients with metastatic melanoma.
M. Atkins +12 more
semanticscholar +1 more source
Expression of interleukin 2 and the interleukin 2 receptor in aging rats
Cellular Immunology, 1989Lymphocytes of aged animals exhibit a marked decrease in proliferative capacity in response to mitogen stimulation when compared to those of younger animals. In humans and mice the decreased proliferation is due at least in part (i) to the inability of lymphocytes to synthesize sufficient interleukin 2 (IL-2) and (ii) to decreased expression of IL-2 ...
Nikki J. Holbrook +6 more
openaire +3 more sources
Biotinylated recombinant interleukin-2
Journal of Immunological Methods, 1988Recombinant interleukin-2 was biotinylated using a N-hydroxyl-succinimidyl [3H]biotin ester. The biotinylated lymphokine retained full binding and growth-promoting activities when assayed on the interleukin-2-dependent murine cell line HT-2. In preliminary studies, biotinylated interleukin-2 was used in conjunction with immunogold staining to ...
Vesna Olivieri +5 more
openaire +4 more sources